Literature DB >> 16528749

[18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies.

Brad A Racette1, Laura Good, Jo Ann Antenor, Lori McGee-Minnich, Stephen M Moerlein, Tom O Videen, Joel S Perlmutter.   

Abstract

Parkinson disease (PD) is a late onset disorder with age-dependent penetrance that may confound genetic studies, since affected individuals may not demonstrate clinical manifestations at the time of evaluation. The use of endophenotypes, biologic surrogates for clinical disease diagnoses, may permit more accurate classification of at-risk subjects. Positron emission tomography (PET) measurements of 6-[18F]fluorodopa ([18F]FDOPA) uptake indicate nigrostriatal neuronal integrity and may provide a useful endophenotype for PD linkage studies. We performed [18F]FDOPA PET in 11 members of a large, multi-incident Amish family with PD, 24 normals and 48 people with clinically definite idiopathic PD (PD controls). Clinical diagnoses in the Amish were clinically definite PD in four, clinically probable in one, clinically possible in five, and normal in one. Abnormal [18F]FDOPA posterior putamen uptake was defined as less than 3 standard deviations below the normal mean. The criteria were applied to the Amish sample to determine a PET endophenotype for each. We performed genetic simulations using SLINK to model the effect phenoconversion with the PET endophenotype had on logarithm of odds (LOD) scores. PET endophenotype confirmed the status of two clinically definite subjects. Two clinically definite Amish PD subjects had normal PETs. Two possible PD were converted to "PET definite PD." The remainder had normal PETs. The average maximum LOD score with the pre-PET was 6.14 +/- 0.84. Simulating phenoconversion of subjects with unknown phenotypes increased the LOD score to 7.36 +/- 1.23. The [18F]FDOPA PET endophenotype permits phenoconversion in multi-incident PD families and may increase LOD score accuracy and power of an informative pedigree. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528749      PMCID: PMC2646004          DOI: 10.1002/ajmg.b.30293

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  32 in total

1.  Pathology of PD in monozygotic twins with a 20-year discordance interval.

Authors:  D Dickson; M Farrer; S Lincoln; R P Mason; T R Zimmerman; L I Golbe; J Hardy
Journal:  Neurology       Date:  2001-04-10       Impact factor: 9.910

2.  [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

Authors:  K Marek; R Innis; C van Dyck; B Fussell; M Early; S Eberly; D Oakes; J Seibyl
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

3.  Levodopa and the progression of Parkinson's disease.

Authors:  Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

Review 4.  Imaging the vesicular monoamine transporter.

Authors:  K A Frey; R A Koeppe; M R Kilbourn
Journal:  Adv Neurol       Date:  2001

5.  Welding-related parkinsonism: clinical features, treatment, and pathophysiology.

Authors:  B A Racette; L McGee-Minnich; S M Moerlein; J W Mink; T O Videen; J S Perlmutter
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

6.  Template images for nonhuman primate neuroimaging: 1. Baboon.

Authors:  K J Black; A Z Snyder; J M Koller; M H Gado; J S Perlmutter
Journal:  Neuroimage       Date:  2001-09       Impact factor: 6.556

7.  A multi-incident, Old-Order Amish family with PD.

Authors:  B A Racette; M Rundle; J C Wang; A Goate; N L Saccone; M Farrer; S Lincoln; J Hussey; S Smemo; J Lin; B Suarez; A Parsian; J S Perlmutter
Journal:  Neurology       Date:  2002-02-26       Impact factor: 9.910

8.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

9.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

Authors:  C S Lee; A Samii; V Sossi; T J Ruth; M Schulzer; J E Holden; J Wudel; P K Pal; R de la Fuente-Fernandez; D B Calne; A J Stoessl
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

10.  Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.

Authors:  Vincenzo Bonifati; Patrizia Rizzu; Marijke J van Baren; Onno Schaap; Guido J Breedveld; Elmar Krieger; Marieke C J Dekker; Ferdinando Squitieri; Pablo Ibanez; Marijke Joosse; Jeroen W van Dongen; Nicola Vanacore; John C van Swieten; Alexis Brice; Giuseppe Meco; Cornelia M van Duijn; Ben A Oostra; Peter Heutink
Journal:  Science       Date:  2002-11-21       Impact factor: 47.728

View more
  9 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

Review 2.  Preservation of function in Parkinson's disease: what's learning got to do with it?

Authors:  Jeff A Beeler
Journal:  Brain Res       Date:  2011-09-29       Impact factor: 3.252

3.  Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression.

Authors:  Almas Siddiqui; Jyothi K Mallajosyula; Anand Rane; Julie K Andersen
Journal:  Neurobiol Dis       Date:  2010-07-21       Impact factor: 5.996

Review 4.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

Review 5.  Neurological and developmental approaches to poor pitch perception and production.

Authors:  Psyche Loui; Steven M Demorest; Peter Q Pfordresher; Janani Iyer
Journal:  Ann N Y Acad Sci       Date:  2015-03       Impact factor: 5.691

6.  A population-based study of parkinsonism in an Amish community.

Authors:  Brad A Racette; Laura M Good; Abigail M Kissel; Susan R Criswell; Joel S Perlmutter
Journal:  Neuroepidemiology       Date:  2009-07-27       Impact factor: 3.282

7.  A genome-wide scan in an Amish pedigree with parkinsonism.

Authors:  S L Lee; D G Murdock; J L McCauley; Y Bradford; A Crunk; L McFarland; L Jiang; T Wang; N Schnetz-Boutaud; J L Haines
Journal:  Ann Hum Genet       Date:  2008-05-21       Impact factor: 1.670

8.  Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

Authors:  R Nandhagopal; E Mak; M Schulzer; J McKenzie; S McCormick; V Sossi; T J Ruth; A Strongosky; M J Farrer; Z K Wszolek; A J Stoessl
Journal:  Neurology       Date:  2008-11-25       Impact factor: 9.910

9.  Heritability of saccadic eye movements in spinocerebellar ataxia type 2: insights into an endophenotype marker.

Authors:  Roberto Rodríguez-Labrada; Yaimeé Vázquez-Mojena; Nalia Canales-Ochoa; Jacqueline Medrano-Montero; Luis Velázquez-Pérez
Journal:  Cerebellum Ataxias       Date:  2017-12-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.